Raddeanin A Inhibits Glioblastoma Growth by Targeting Skp2
Author Information
Author(s): Jia Weiqiang, Zhang Yanling, Zhao Qiang, Gong Min, Cao Yang, Liu Jia, Luo Shuang
Primary Institution: Cancer Prevention and Treatment Institute of Chengdu, Department of Neurosurgery, Chengdu Fifth People's Hospital
Hypothesis
Raddeanin A could modulate Skp2 expression, thereby influencing the EMT process and the maintenance of GSCs.
Conclusion
Raddeanin A shows significant antitumor efficacy against glioblastoma by downregulating Skp2 and inhibiting pathways linked to stemness and EMT.
Supporting Evidence
- Raddeanin A significantly reduced the proliferation of glioblastoma cells in a concentration-dependent manner.
- RA treatment led to decreased expression of Skp2 and stemness markers in glioblastoma stem-like cells.
- RA inhibited migration and invasion of glioblastoma cells in vitro.
- RA showed significant antitumor effects in vivo in xenograft models.
Takeaway
Raddeanin A is a natural compound that helps fight a type of brain cancer by stopping cancer cells from growing and spreading.
Methodology
The study used cell viability assays, colony formation assays, Transwell assays, RT-PCR, western blotting, and in vivo xenograft models to assess the effects of Raddeanin A on glioblastoma cells.
Limitations
The study lacks direct experimental evidence of Raddeanin A's interaction with Skp2 and has not fully explored the underlying signaling pathways.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website